Iohexol (DrugBank: Iohexol)
2 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
19 | Lysosomal storage disease | 2 |
67 | Polycystic kidney disease | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01839526 (ClinicalTrials.gov) | May 2013 | 11/4/2013 | A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease | A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease | Fabry Disease | Drug: Iohexol | Genzyme, a Sanofi Company | NULL | Terminated | 5 Years | 25 Years | Male | 39 | N/A | United States;Argentina;Austria;Belgium;Brazil;Canada;Finland;France;Hungary;Norway;Poland;Spain;Taiwan;United Kingdom |
2 | EUCTR2012-001966-14-ES (EUCTR) | 25/10/2012 | 03/09/2012 | A study to assess the renal function in young male patients with Fabry disease who have never received any specific treatment for this disease. | A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients with Fabry Disease - FABRY-MAP | Fabry disease MedDRA version: 15.0;Level: PT;Classification code 10016016;Term: Fabry's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Trade Name: Iohexol Product Name: OMNIPAQUE Product Code: Not applicable INN or Proposed INN: iohexol Other descriptive name: iohexol | Genzyme, a Sanofi Company | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 45 | United States;Canada;Spain;Norway;Netherlands;United Kingdom |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04407481 (ClinicalTrials.gov) | November 1, 2020 | 19/5/2020 | PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN) | PENGUIN: PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD | Polycystic Kidney Disease, Adult;Polycystic Kidney, Autosomal Dominant | Drug: Aminohippurate Sodium Inj 20%;Drug: Iohexol Inj 300 milligrams per milliliter (MG/ML);Radiation: PET/CT Scan | University of Colorado Denver School of Medicine Barbara Davis Center | NULL | Recruiting | 18 Years | 40 Years | All | 20 | United States |